New study using psilocybin to treat depression
Psilocybin, the psychoactive compound from magic mushrooms, is being used to treat depression and anxiety in terminally ill patients in a new trial at Melbourne’s St Vincent’s Hospital.
Renewed interest in psychedelics
Prestigious international institutions have initiated robust psychedelic research programs. Does Australia risk being left behind if it doesn’t do the same?
Psychedelic Drugs Could be the Answer
New research published in the Australian Psychologist Journal claims Australia is missing out on the benefits of using psychedelic drugs to treat a range of mental health illnesses.
The need for Psychedelic Research
On 9th April 2018 The Project (Channel Ten) interviewed PRISM co-founders Dr Stephen Bright and Steve McDonald about the need for Australia to embrace formal research into psychedelic medicines.
Australia is Missing Out
Australia is missing out on a global “renaissance” of research into use of psychedelic drugs to treat mental health problems, two psychologists say.
THE PSYCHEDELIC RENAISSANCE
PRISM President Dr Martin Williams talks with ABC Radio’s Beyond the Lab about the Psychedelic Renaissance.
MDMA designated as ‘breakthrough therapy’
In a press release dated 26 August 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the US Food and Drug Administration has granted ‘Breakthrough Therapy’ designation for MDMA-assisted psychotherapy for PTSD.
TEDx: The Psychedelic Renaissance
Dr Stephen Bright speaking at TEDx UniMelb on the psychedelic renaissance.
MDMA could help treat veterans with PTSD, scientists say
Scientists believe the illegal drug MDMA, also known as ecstasy, has an untapped potential to treat post-traumatic stress disorder (PTSD). But they say plans to test the drug on war veterans in Australia are being stifled by “academic conservatism”. Current treatments for PTSD sufferers can involve a person being exposed to their trauma for weeks […]
EGA 2017 Outdoor Psychedelic Symposium
PRISM is a proud sponsor of the Entheogenesis Australis 2017 Outdoor Psychedelic Symposium. For over a decade Entheogenesis Australis has provided a major meeting place for ethnobotanical enthusiasts and specialists in Australia to share information and create community. The aims of the EGA conference are to address the issues relating to drug use from social, cultural […]
A Critical Analysis of Psychedelics and Psychology
This presentation was delivered by PRISM Vice-President Dr Stephen Bright at a fundraising seminar and dinner held at The Melbourne Brain Centre, Parkville on 8th April 2016.
Psychedelic medical research in Australia: The long and winding road
This presentation was delivered by PRISM President Dr Martin Williams at a fundraising seminar and dinner held at The Melbourne Brain Centre, Parkville on 8th April 2016.
Reflections on Beyond Psychedelics 2016
PRISM Vice President Dr Stephen Bright reflects on his attendance as a guest speaker at Beyond Psychedelics 2016 in Prague.
The Psychedelia Podcast: Interview with Stephen Bright
Dr Stephen Bright talks to The Psychedelia Podcast about the problems facing the psychedelic movement in Australia
The Project on microdosing & MDMA therapy
The Project covers Microdosing & MDMA therapy with Dr Stephen Bright (NDRI & PRISM)
Tweets
- Join us tomorrow in Brisbane for the screening of From Shock to Awe at Kindler Theatre QUT, 1.30pm. Details and tic… https://t.co/Q5GakYT4tj 2 days ago
- PRISM co-founder Steve McDonald and US filmmaker Mitch Schultz will be in Brisbane for the screening of From Shock… https://t.co/RprZFichXO 4 days ago
- New insights into how a mammalian brain naturally produces psychedelic DMT https://t.co/smUftsnUmK 1 week ago
- RT @NyckJeanes : @PRISMNews @Stevemc1 Tickets here: https://t.co/NvywCXWDqJ 2 weeks ago
PRISM Inc (ABN 96 575 647 082) is registered as a charity with the Australian Charities and Not-for-profits Commission ABN 96 575 647 082.
All donations over $2 are tax deductible in Australia.